Akero Therapeutics Inc (AKRO)
21.57
-0.56
(-2.53%)
USD |
NASDAQ |
May 07, 10:20
Akero Therapeutics Cash from Financing (Quarterly): 0.502M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.502M |
| September 30, 2023 | 0.806M |
| June 30, 2023 | 336.86M |
| March 31, 2023 | 15.15M |
| December 31, 2022 | 2.723M |
| September 30, 2022 | 217.90M |
| June 30, 2022 | 34.88M |
| March 31, 2022 | 0.132M |
| December 31, 2021 | 0.243M |
| September 30, 2021 | 0.069M |
| June 30, 2021 | 0.266M |
| March 31, 2021 | 0.024M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.059M |
| September 30, 2020 | 202.78M |
| June 30, 2020 | 0.10M |
| March 31, 2020 | 0.164M |
| December 31, 2019 | 0.115M |
| September 30, 2019 | -1.607M |
| June 30, 2019 | 98.20M |
| March 31, 2019 | -0.72M |
| December 31, 2018 | 70.22M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 14.78M |
| March 31, 2018 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.607M
Minimum
Sep 2019
336.86M
Maximum
Jun 2023
47.86M
Average
0.266M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 479.92M |
| 89bio Inc | 162.17M |
| Viking Therapeutics Inc | 606.04M |
| Eli Lilly and Co | -311.30M |
| Ionis Pharmaceuticals Inc | 40.72M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -48.63M |
| Cash from Investing (Quarterly) | 12.79M |
| Free Cash Flow | -145.37M |
| Free Cash Flow Per Share (Quarterly) | -0.8722 |
| Free Cash Flow Yield | -12.83% |